alexsl
Allogene Therapeutics (NASDAQ:ALLO) shares fell after its first-quarter results cited a delay for a key trial readout, prompting a downgrade at Citizens to Market Perform from Market Outperform.
The company said that the lymphodepletion regimen selection and futility analysis for